Vedolizumab: First global approval

Drugs

Volumn 74, Issue 11, 2014, Pages 1293-1303

  Poole, Raewyn M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; LDP 002; MLN 002; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; COUGHING; CROHN DISEASE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; FATIGUE; FEVER; HEADACHE; HEPATITIS; HUMAN; INFLUENZA; INFUSION RELATED REACTION; NAUSEA; OROPHARYNX PAIN; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; QUALITY OF LIFE; RASH; RHINOPHARYNGITIS; SINUSITIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG APPROVAL; GASTROINTESTINAL AGENTS; HUMANS;

EID: 84904742519     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0253-1     Document Type: Article

References (44)

1. Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579-94.
2. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy. 2012;4(9):883-98.
3. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29(4):397-404.
4. Krishnareddy S, Swaminath A. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol. 2014;20(5):1139-46.
5. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1-18.
6. Holmes D. Integrin inhibitors go with the gut. Nat Rev Drug Discov. 2013;12(6):411-2.
7. Cominelli F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med. 2013;369(8):775-6.
8. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264(1-2):123-6.
9. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int. 2002;52(5-6):367-74. (Pubitemid 34748219)
10. US Food and Drug Administration. FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. 2014. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm398065.htm. Accessed 5 June 2014.
11. Takeda Pharmaceuticals America Inc. Prescribing information ENTYVIO (vedolizumab) for injection, for intravenous use. 2014. http://general. takedapharm.com/content/file.aspx?filetypecode=ENTYVIOPI&CountryCode= US&LanguageCode=EN&cacheRandomizer=452533ef-ab7b-4140-922a-a97734127102. Accessed 5 June 2014.
12. US Food and Drug Administration. BLA approval (BLA125476/0). 2014. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/125476Orig1s000ltr. pdf. Accessed 5 June 2014.
13. European Medicines Agency. EMA recommends approval of a locally targeted treatment for ulcerative colitis and Crohn's disease. 2014. http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2014/03/WC500163496.pdf. Accessed 5 June 2014.
14. Takeda. Takeda receives European commission marketing authorisation for Entyvio® (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease (media release); 28 May 2014. http://www.takeda.com/news/2014/20140528- 6590.html.
15. Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc. Takeda completes acquisition of millennium (media release); 14 May 2008. http://www.takeda.com.
16. Millennium Pharmaceuticals Inc. Millennium reports second quarter 2004 financial results (media release); 22 July 2004. http://www.millennium.com.
17. Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. mAbs. 2013;5(6):842-50.
18. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499-507. (Pubitemid 41007865)
19. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470-9.
20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin (erratum appears in Clin Gastroenterol Hepatol. 2009;7(4):494). Clin Gastroenterol Hepatol. 2008;6(12):1370-7.
21. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
22. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
23. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2014;. doi:10.1136/gutjnl-2014-307127.
24. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691-9.
25. Rosario M, Fox I, Milch C, et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 (abstract no. P-140). Inflamm Bowel Dis. 2013;19(suppl):S80.
26. Rosario M, Wyant T, Milch C, et al. Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from the GEMINI 1 and 2 studies (abstract no. DOP058). J Crohns Colitis. 2014;8(suppl 1):S42-S43.
27. Rosario M, Dirks N, Gastonguay M, et al. Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease (abstract no. P385). J Crohns Colitis. 2014;8(suppl 1):S225-6.
28. Dirks NL, Rosario M, Gastonguay MR, et al. Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn's disease (abstract no. M01225). Gastroenterology. 2014;1(suppl):S-591.
29. French J, Rosario M, Dirks NL, et al. Vedolizumab exposure-response relationship during induction therapy in adults with Crohn's disease (abstract no. Mo1231). Gastroenterology. 2014;1(suppl):S592-3.
30. French J, Rosario M, Dirks NL, et al. Exposure-response relationship of vedolizumab treatment in adults with ulcerative colitis (abstract no. Mo1229). Gastroenterology. 2014;1(suppl):S-592.
31. Rosario M, French J, Dirks N, et al. Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis (abstract no. P489). J Crohns Colitis. 2014;8 (suppl 1):S270-S271.
32. Rosario M, French J, Dirks N, et al. Exposure response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease (abstract no. P488). J Crohns Colitis. 2014;8 (suppl 1):S270.
33. Feagan B, Sands B, Sankoh S, et al. Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (abstract no. O-1b). Inflamm Bowel Dis. 2012;18(Suppl. 1):S1-2.
34. Feagan B, Sandborn WJ, Smyth M, et al. Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders (abstract no. P501). J Crohns Colitis. 2014;8(suppl):S276-7.
35. Sands B, Hanauer S, Colombel JF, et al. Reductions in corticosteroid use in patients with ulcerative colitis or Crohn's disease treated with vedolizumab (abstract no. 1676). Am J Gastroenterol. 2013;108(suppl):S503.
36. Feagan BG, Colombel JF, Rubin DT, et al. Health-related quality of life in patients with ulcerative colitis after treatment with vedolizumab: results from the GEMINI 1 study (abstract no. Mo1223). Gastroenterology. 2014;1(suppl):S-590.
37. Sandborn WJ, Feagan B, Reinisch W, et al. Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 (abstract no. P497). J Crohns Colitis. 2014;8(suppl):S274-S275.
38. Hanauer S, Colombel JF, Feagan B, et al. Vedolizumab maintenance therapy for Crohn's disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial (abstract no. 1522). Am J Gastroenterol. 2012;107(suppl): S620-1.
39. Sands B, Feagan B, Rutgeerts P, et al. Vedolizumab induction therapy for patients with Crohn's disease and prior anti-TNF antagonist failure: a randomized, placebo-controlled, doubleblind, multicenter trial (abstract no. P-26). Inflamm Bowel Dis. 2012;18(Suppl):S24-5.
40. Feagan BG, McDonald JW, Wild G, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (abstract no. 4851). Gastroenterology. 2000;118 (suppl 4 part 1):A874.
41. Parikh A, Paolino J, Fedy ER, et al. No association between vedolizumab exposure and serum JC virus levels (abstract). J Crohns Colitis. 2011;5 (suppl 1):S109-10.
42. Millennium Pharmaceuticals. An open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn's disease (GEMINI LTS) (ClinicalTrials.gov identifier NCT00790933). US National Institutes of Health, ClinicalTrials. gov. 2008. http://clinicaltrials.gov/ct2/show/NCT00790933?term= NCT00790933&rank=1. Accessed 9 June 2014.
43. Takeda. Phase III study of MLN0002 (300 mg) in the treatment of ulcerative colitis (ClinicalTrials.gov identifier NCT02039505). US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/ show/NCT02039505?term=NCT02039505&rank=1. Accessed 9 June 2014.
44. Takeda. Phase III study of MLN0002 (300 mg) in treatment of Crohn's disease (ClinicalTrials.gov identifier NCT02038920). US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/ NCT02038920?term=NCT02038920&rank=1. Accessed 9 June 2014.